# Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT01349049** · PHASE1,PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 90 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** PLX3397
- **DRUG:** PLX3397

## Key facts

- **NCT ID:** NCT01349049
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-21
- **Primary completion:** 2015-01-20
- **Final completion:** 2018-01-09
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349049, "Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01349049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*